Inovio Biomedical Corporation: First Human Demonstration of Significant, Persistent Antibody Response Using Electroporation-Delivered DNA Vaccine Published in Human Gene Therapy

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today new data representing what Inovio believes to be the first demonstration of a significantly increased and persistent level of antibody response generated by a DNA vaccine delivered using electroporation.